JP2021534154A5 - - Google Patents

Info

Publication number
JP2021534154A5
JP2021534154A5 JP2021507686A JP2021507686A JP2021534154A5 JP 2021534154 A5 JP2021534154 A5 JP 2021534154A5 JP 2021507686 A JP2021507686 A JP 2021507686A JP 2021507686 A JP2021507686 A JP 2021507686A JP 2021534154 A5 JP2021534154 A5 JP 2021534154A5
Authority
JP
Japan
Prior art keywords
aso
administered
combination according
subject
raav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021507686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534154A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046720 external-priority patent/WO2020037161A1/en
Publication of JP2021534154A publication Critical patent/JP2021534154A/ja
Publication of JP2021534154A5 publication Critical patent/JP2021534154A5/ja
Priority to JP2024096579A priority Critical patent/JP2024111074A/ja
Priority to JP2025187453A priority patent/JP2026009384A/ja
Withdrawn legal-status Critical Current

Links

JP2021507686A 2018-08-15 2019-08-15 脊髄性筋萎縮症のための併用療法 Withdrawn JP2021534154A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024096579A JP2024111074A (ja) 2018-08-15 2024-06-14 脊髄性筋萎縮症のための併用療法
JP2025187453A JP2026009384A (ja) 2018-08-15 2025-11-06 脊髄性筋萎縮症のための併用療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862764893P 2018-08-15 2018-08-15
US62/764,893 2018-08-15
US201862783189P 2018-12-20 2018-12-20
US62/783,189 2018-12-20
PCT/US2019/046720 WO2020037161A1 (en) 2018-08-15 2019-08-15 Combination therapy for spinal muscular atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024096579A Division JP2024111074A (ja) 2018-08-15 2024-06-14 脊髄性筋萎縮症のための併用療法

Publications (2)

Publication Number Publication Date
JP2021534154A JP2021534154A (ja) 2021-12-09
JP2021534154A5 true JP2021534154A5 (enExample) 2022-08-22

Family

ID=69525927

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021507686A Withdrawn JP2021534154A (ja) 2018-08-15 2019-08-15 脊髄性筋萎縮症のための併用療法
JP2024096579A Pending JP2024111074A (ja) 2018-08-15 2024-06-14 脊髄性筋萎縮症のための併用療法
JP2025187453A Pending JP2026009384A (ja) 2018-08-15 2025-11-06 脊髄性筋萎縮症のための併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024096579A Pending JP2024111074A (ja) 2018-08-15 2024-06-14 脊髄性筋萎縮症のための併用療法
JP2025187453A Pending JP2026009384A (ja) 2018-08-15 2025-11-06 脊髄性筋萎縮症のための併用療法

Country Status (4)

Country Link
US (2) US20210308281A1 (enExample)
EP (1) EP3837374A4 (enExample)
JP (3) JP2021534154A (enExample)
WO (1) WO2020037161A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64879B1 (sr) * 2019-07-19 2023-12-29 Biogen Ma Inc Postupci za lečenje ili prevenciju spinalne mišićne atrofije
EP4013387A4 (en) * 2019-08-15 2023-09-27 Biogen MA Inc. COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY
IL300287A (en) * 2020-07-31 2023-04-01 Ractigen Therapeutics Combined treatment of SMA with SARNA and mRNA modulators
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treatment of spinal muscular atrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084437A (ko) * 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
AU2016370630B2 (en) * 2015-12-14 2023-04-13 The Trustees Of The University Of Pennsylvania Adeno-associated viral vectors useful in treatment of spinal muscular atropy
EP4585229A3 (en) * 2017-11-08 2026-01-14 Novartis AG Means and method for preparing viral vectors and uses of same
JP7478675B2 (ja) * 2018-06-08 2024-05-07 ノバルティス アーゲー 薬物製品の効力を測定するための細胞ベースアッセイ
EP3886919A1 (en) * 2018-11-30 2021-10-06 Novartis AG Aav viral vectors and uses thereof

Similar Documents

Publication Publication Date Title
Kulkarni et al. The current landscape of nucleic acid therapeutics
CN109477109B (zh) 靶向人lmna的寡核苷酸类似物
RU2566724C9 (ru) Композиции и способы модуляции smn2 сплайсинга у субъекта
JP2023523237A (ja) ｓｎＲＮＡ構成要素を使用する組成物及び方法
JP2022526018A5 (enExample)
Muntoni et al. Genetic treatments in muscular dystrophies
JP2021534809A (ja) Ａａｖカプシドの向性の再指向化
JP2024513949A5 (enExample)
JP2023524291A5 (enExample)
BR112014009066B1 (pt) molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica
CN110325219B (zh) 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
TW201811807A (zh) 用於肌肉萎縮症之外顯子跳躍寡聚物
JP2022533358A5 (enExample)
JP2024517143A5 (enExample)
JP2021534154A (ja) 脊髄性筋萎縮症のための併用療法
JP2024540537A5 (enExample)
JP2020527167A5 (enExample)
ES2918975T3 (es) Tratamiento de la distrofia facioescapulohumeral
WO2022192708A1 (en) Noninvasive aav vectors for highly efficient gene delivery to the nervous system
JP2016518820A5 (enExample)
KR20240063110A (ko) 치료제의 역행성 관상 정맥 또는 정맥동 투여
WO2017186815A1 (en) Antisense oligonucleotides for enhanced expression of frataxin
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
WO2018035457A1 (en) Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
JP2022530359A5 (enExample)